



DEK-AFF2 fusion-associated papillary squamous cell carcinoma of the sinonasal tract – A systematic review.

Dr. Karthik Shunmugavelu^{1*}, Antowin Leo², Dr. Velusamy Nathiyal³

¹Assistant Professor, Department of Dentistry, PSP Medical College Hospital and Research Institute, Tambaram Kanchipuram main road, Oragadam Panruti Kanchipuram district Tamilnadu 631604 India

²Undergraduate (MBBS), PSP Medical College Hospital and Research Institute, Tambaram, Kanchipuram main road Oragadam Panruti Kanchipuram district Tamilnadu 631604 India

³Assistant Professor, PSP Medical College Hospital and Research Institute, Tambaram, Kanchipuram main road, Oragadam Panruti Kanchipuram district, Tamil Nadu 631604 India

Abstract

Background

Papillary squamous cell carcinoma of the sinonasal tract is an uncommon malignancy with diverse histopathological features and poorly understood molecular drivers. Recently, a recurrent DEK-AFF2 gene fusion has been reported in a subset of sinonasal squamous cell carcinomas displaying papillary architecture and deceptively bland morphology. The objective of this systematic review was to evaluate current evidence regarding the clinicopathological and molecular association between DEK-AFF2 fusion and papillary squamous cell carcinoma of the sinonasal tract.

Methods

A systematic literature search was conducted following PRISMA guidelines. Electronic databases, including MEDLINE, PubMed, Scopus, Embase, Web of Science, and LILACS, were searched for studies published between 2020 and 2024. Eligibility criteria included original research articles reporting clinicopathological or molecular characteristics of sinonasal papillary squamous cell carcinoma associated with DEK-AFF2 fusion. Data items extracted included author, year, study design, molecular findings, and clinical outcomes. Study quality was evaluated using the STROBE checklist. A qualitative synthesis of eligible studies was performed.

Results

Four studies met the inclusion criteria. The reviewed literature consistently demonstrated that DEK-AFF2 fusion defines a distinct subset of sinonasal squamous cell carcinoma characterized by papillary growth patterns, bland cytological features, and molecular alterations distinct from conventional sinonasal papillomas or HPV-associated carcinomas. These tumors frequently lacked EGFR or KRAS mutations and typically tested negative for transcriptionally active human papillomavirus. Despite their deceptively low-grade morphology, several studies reported local recurrence and aggressive clinical behavior.

Conclusion

DEK-AFF2 fusion-associated papillary squamous cell carcinoma represents an emerging molecular subtype of sinonasal carcinoma with unique histopathological and genetic characteristics. Recognition of this entity is important for accurate diagnosis and clinical management.

Future research

Further multi-institutional studies integrating genomic sequencing and long-term clinical follow-up are required to clarify the biological mechanisms, diagnostic criteria, and therapeutic implications of DEK-AFF2 fusion in sinonasal carcinomas.

Keywords: Sinonasal squamous cell carcinoma, Human Papillomavirus, Papillary squamous cell carcinoma, Oral cavity, Gingiva, Alveolar ridge, Head and neck

Submitted: January 10, 2026 **Accepted:** February 18, 2026 **Published:** March 01, 2026

Corresponding author: Dr.Karthik Shunmugavelu*

Email: drkarthiks1981@gmail.com

<https://orcid.org/0000-0001-7562-8802>

Assistant Professor, Department of Dentistry, PSP Medical College Hospital and Research Institute, Tambaram, Kanchipuram main road, Oragadam, Panruti, Kanchipuram district, Tamil Nadu 631604 India



Introduction

In the oral cavity, oral squamous cell carcinoma (OSCC) is thought to be the most prevalent malignant epithelial neoplasm. The floor of the mouth, lips, and tongue are the areas most frequently impacted by OSCC. Either a potentially malignant oral lesion may precede it, or it may develop in an apparently normal mucosa. A rare form of squamous cell carcinoma (SCCA), papillary squamous cell carcinoma (PSCCA) has a better prognosis than standard SCCA and an exophytic and papillary appearance. The most frequently impacted area of the head and neck is the larynx. The oral cavity, oropharynx, sinonasal tract, and nasopharynx are other areas of involvement.

Cases have been documented in the ventral tongue, floor of the mouth, alveolar ridge, oral mucosa, and, infrequently, other regions of the oral cavity. A link to varied degrees with the human papillomavirus (HPV) has been shown within head and neck PSCCA. The larynx is where head and neck PSCCA is most prevalent and has the best prognosis. The prognosis for the sinonasal tract has been thought to be the worst. According to 2011 research of 52 instances of PSCCA of the head and neck, the larynx was the most often affected head and neck region, followed by the oral cavity (34.6%), the sinonasal tract (15.4%), and the oropharynx (13.5%). According to writers in 2000, the larynx is the most frequently affected, whereas the oral cavity and oropharynx are less frequently impacted than the sinonasal tract.

Although two big studies have subcategorized oral cavity PSCCA, many previous investigations of PSCCA rarely specify specific areas in the oral cavity. The gingiva is the most common site for PSCCA, followed, in decreasing order of prevalence, by the buccal mucosa, lateral tongue, palate, and lower lip. Studies comparing 56 cases of PSCCA to oral squamous papillomas support this finding. Additionally, research conducted in 1994 identified 52 cases of PSCCA in the oropharynx and oral cavity. In this study, the alveolar ridge was reported as the most frequent site for the cases examined.

The buccal mucosa, floor of the mouth, ventral tongue, retromolar pad, lateral tongue, and palate were the next most common locations, listed in decreasing order. Recently, four cases of basaloid non-keratinizing squamous cell carcinoma (SCC) were identified in the middle ear and sinonasal tract, all exhibiting high-grade morphology. These cases were found to have a unique DEK-AFF2 fusion. The presence of DEK-AFF2 fusions in cancers may be of clinical significance, particularly highlighted by the first documented case, which showed a remarkable response to immune checkpoint inhibitors. The objective of this systematic review is to evaluate the available scientific evidence regarding the association

between the DEK-AFF2 gene fusion and papillary squamous cell carcinoma of the sinonasal tract.

Methodology

Eligibility criteria

Studies were considered eligible if they investigated the clinicopathological, molecular, or diagnostic characteristics of **DEK-AFF2 fusion-associated papillary squamous cell carcinoma of the sinonasal tract**. Original research articles published between January 2020 and December 2024 were included. Studies describing molecular identification of DEK-AFF2 fusion, clinicopathological characterization of sinonasal papillary squamous cell carcinoma, or molecular diagnostic evaluation of this tumor entity were considered relevant. Exclusion criteria included review articles, conference abstracts, editorials, letters to the editor, studies unrelated to sinonasal papillary squamous cell carcinoma, studies lacking molecular data related to DEK-AFF2 fusion, and non-human studies.

Eligible studies were grouped according to their focus on molecular characterization, clinicopathological features, or clinical outcomes of DEK-AFF2 fusion-associated tumors.

Information sources

A comprehensive literature search was conducted using the electronic databases **MEDLINE, PubMed, Scopus, Embase, Web of Science, and LILACS**. Reference lists of relevant articles were also screened to identify additional studies. The final search of all databases was performed in **December 2024**.

Search strategy

The search strategy used a combination of keywords and Boolean operators. The primary search terms included: "DEK-AFF2 fusion" AND "sinonasal squamous cell carcinoma"

Additional combinations included:

"DEK-AFF2" AND "papillary squamous cell carcinoma"

"sinonasal carcinoma" AND "DEK fusion"

"sinonasal squamous carcinoma" AND "human papillomavirus"

Search filters were applied to restrict the results to studies published in **English between 2020 and 2024**.



Selection process

Study selection was conducted in two stages. In the first stage, titles and abstracts retrieved from the database search were screened for relevance. In the second stage, full-text articles of potentially eligible studies were reviewed against the predefined inclusion criteria. The selection process followed the **PRISMA guidelines**, and the final eligible studies were included in the qualitative synthesis.

Data collection process

Data extraction from the included studies was performed using a standardized data collection approach. Extracted information included author name, year of publication, country of study, study design, molecular findings, histopathological characteristics, and clinical outcomes related to DEK-AFF2 fusion-associated tumors.

Data items

The primary outcomes assessed in this review included:
Presence of the **DEK-AFF2 gene fusion**
Histopathological characteristics of papillary sinonasal squamous cell carcinoma
Molecular alterations associated with this tumor entity
Clinical behavior and patient outcomes
Additional variables collected included study design, diagnostic methods used for detecting gene fusion, and molecular markers reported in each study.

Study risk of bias assessment

The methodological quality of the included studies was assessed using the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) checklist. This tool evaluates reporting quality, study design transparency, and potential sources of bias in observational research.

Effect measures

Due to differences in study design and the limited number of studies, effect measures such as risk ratios or mean differences were not calculated. Instead, study findings were summarized qualitatively.

Synthesis methods

A qualitative synthesis was performed to summarize the results of the included studies. Data were organized into tables summarizing study characteristics, molecular

findings, and clinical outcomes. Patterns and similarities among the studies were analyzed to identify consistent clinicopathological features of DEK-AFF2 fusion-associated tumors.

Reporting bias assessment

Because of the limited number of eligible studies, a formal statistical assessment of reporting bias was not conducted. However, multiple databases were searched to reduce the possibility of publication bias.

Certainty assessment

The overall certainty of evidence was evaluated qualitatively based on study design, methodological quality, and consistency of reported findings among the included studies.

Results

Study selection

The database search across MEDLINE, PubMed, Scopus, Embase, Web of Science, and LILACS identified 10 potentially relevant records published between 2020 and 2024. After screening titles and abstracts, 6 studies were excluded because they did not meet the eligibility criteria. The reasons for exclusion included review articles, studies not investigating DEK-AFF2 fusion, studies unrelated to sinonasal papillary squamous cell carcinoma, or insufficient molecular data.

Following full-text assessment, 4 studies fulfilled the inclusion criteria and were included in the qualitative synthesis. The process of study identification, screening, eligibility assessment, and final inclusion is illustrated in the PRISMA flow diagram (Figure 1).

Study characteristics

Four studies published between 2021 and 2025 investigated the clinicopathological and molecular features of DEK-AFF2 fusion-associated papillary squamous cell carcinoma of the sinonasal tract. These studies included case series and multi-institutional clinicopathological analyses. The main characteristics of the included studies are summarized in Table 1, while the principal clinical and molecular findings are presented in Table 2.

The included studies consistently reported that DEK-AFF2 fusion defines a distinct subset of sinonasal squamous cell carcinoma characterized by papillary architecture, deceptively bland cytological features, and



molecular profiles different from conventional sinonasal papillomas or HPV-associated carcinomas.

Table 1 – Characteristics of included studies on DEK-AFF2 fusion-associated sinonasal papillary squamous cell carcinoma

Author	Study Title	Journal	Study Design
Kuo et al.	DEK-AFF2 fusion-associated papillary squamous cell carcinoma of the sinonasal tract	Modern Pathology	Clinicopathologic case series
Wartenberg et al.	Differentiated papillary NUT carcinoma of the sinonasal tract	Head and Neck Pathology	Case report
Zhao et al.	DEK-AFF2-associated papillary squamous cell carcinoma	Head and Neck Pathology	Clinicopathologic analysis
Hart et al.	DEK-AFF2 fusion sinonasal nonkeratinizing SCC	American Journal of Surgical Pathology	Multi-institutional outcome study

Page | 4

Table 2 - Key molecular and clinical findings reported in the included studies

Author	Key Findings
Kuo et al.	Identified DEK-AFF2 fusion in sinonasal papillary SCC with deceptively bland morphology
Wartenberg et al.	Demonstrated molecular diversity among papillary sinonasal carcinomas
Zhao et al.	Reported clinicopathological features and aggressive behavior associated with DEK-AFF2 fusion
Hart et al.	Observed frequent local recurrence, but survival rates comparable to conventional sinonasal SCC.

Risk of bias in included studies

The methodological quality of the included studies was assessed using the STROBE checklist. Overall, the studies demonstrated moderate methodological quality. Most studies clearly reported patient characteristics, diagnostic techniques used for identifying DEK-AFF2 fusion, and histopathological findings. However, several studies were limited by small sample sizes and retrospective designs, which may introduce potential selection bias.

Results of individual studies

Each included study provided evidence supporting the association between the DEK-AFF2 gene fusion and papillary squamous cell carcinoma of the sinonasal tract. Kuo et al. described a series of cases demonstrating papillary architecture and deceptively bland cytological features associated with DEK-AFF2 fusion. Zhao et al. reported clinicopathological characteristics of several cases and highlighted aggressive biological behavior despite low-grade morphological appearance. Hart et al. conducted a multi-institutional study and observed that patients with DEK-AFF2 fusion tumors often experienced local recurrence, but overall survival rates were comparable to conventional sinonasal squamous cell carcinoma. Wartenberg et al. described additional molecular variants of papillary sinonasal carcinoma,

contributing to the understanding of molecular heterogeneity within this tumor group.

Results of syntheses

Qualitative synthesis of the included studies suggests that DEK-AFF2 fusion represents a molecularly distinct subtype of sinonasal papillary squamous cell carcinoma. Across studies, tumors exhibited similar histological characteristics, including papillary architecture, basaloid or non-keratinizing epithelial morphology, and relatively uniform cytological features. Molecular analyses indicated that these tumors often lacked common oncogenic alterations seen in sinonasal papillomas, such as EGFR or KRAS mutations.

Due to differences in study design, sample size, and diagnostic methods, quantitative meta-analysis was not performed.

Reporting bias

Formal statistical evaluation of reporting bias was not conducted because only four studies met the inclusion criteria. However, the search strategy included multiple databases and reference list screening to reduce potential publication bias.

Certainty of evidence

The overall certainty of evidence was considered **moderate**. While the included studies consistently identified DEK-AFF2 fusion as a defining molecular alteration in this tumor subtype, the limited number of studies and small sample sizes reduce the strength of conclusions.

DISCUSSION

Papillary squamous cell carcinoma represents an uncommon histological variant of squamous cell carcinoma characterized by exophytic papillary growth and distinctive architectural patterns. Although conventional oral squamous cell carcinoma (OSCC) remains the most frequently encountered malignant epithelial tumor of the oral cavity, papillary variants demonstrate unique biological and morphological characteristics that distinguish them from typical squamous cell carcinomas [1,2]. In many cases, these tumors may arise from apparently normal mucosa or develop in association with potentially malignant disorders such as leukoplakia or proliferative verrucous leukoplakia [2].

Papillary squamous cell carcinoma has been described as a relatively uncommon subtype of squamous cell carcinoma that often demonstrates a more favorable clinical outcome compared with conventional carcinomas. The lesion typically presents with papillary epithelial proliferation and limited stromal invasion, which contributes to a lower incidence of nodal metastasis and improved survival in some anatomical locations [3]. Prognostic outcomes in squamous cell carcinoma are influenced by multiple histopathological parameters, including depth of invasion, pattern of tumor infiltration, perineural and lymphovascular invasion, and tumor-stromal interactions [4].

The tumor microenvironment plays an important role in tumor development and progression. Among the cellular components of the tumor microenvironment, cancer-associated fibroblasts (CAFs) have been shown to influence tumor invasion, angiogenesis, and metastatic behavior [5]. Increased CAF density has been associated with aggressive tumor features such as lymph node metastasis, vascular invasion, and tumor recurrence [6]. Several signaling pathways contribute to the activation of fibroblasts within tumor stroma, including transforming growth factor- β (TGF- β), which regulates cellular proliferation, extracellular matrix remodeling, and fibrotic responses [7]. Activation of fibroblasts through these pathways leads to the expression of α -smooth muscle actin (α -SMA), a marker commonly used to identify myofibroblasts within tumor stroma [8,9].

Papillary squamous cell carcinoma (PSCCA) has been reported in multiple regions of the head and neck, including the larynx, oral cavity, oropharynx, and sinonasal tract [10,11]. Among these sites, the larynx is considered the most common location, whereas sinonasal tumors appear less frequently but may demonstrate more aggressive clinical behavior [14]. Several clinicopathological studies have documented the anatomical distribution of PSCCA within the head and neck region, with the larynx accounting for approximately one-third of reported cases, followed by the oral cavity, sinonasal tract, and oropharynx [14].

In the oral cavity, papillary squamous cell carcinoma has been described in multiple locations, including the gingiva, alveolar ridge, buccal mucosa, and tongue [15]. Some investigations have noted an association between papillary carcinoma and preexisting lesions such as proliferative verrucous leukoplakia, suggesting that certain mucosal alterations may predispose to tumor development [17]. Nevertheless, the overall prevalence of papillary squamous cell carcinoma within the oral cavity remains relatively low compared with conventional squamous cell carcinoma [16].

Histologically, papillary squamous cell carcinoma shares certain architectural similarities with other well-differentiated squamous neoplasms such as verrucous carcinoma. However, important morphological differences exist. Verrucous carcinoma is characterized by heavily keratinized epithelium with broad pushing borders and minimal cytological atypia, whereas papillary squamous cell carcinoma shows papillary epithelial proliferation with variable cytological atypia and malignant potential [12,13].

Recent molecular studies have identified novel genetic alterations associated with sinonasal squamous cell carcinomas. One such alteration is the **DEK-AFF2 gene fusion**, which has emerged as a distinctive molecular feature in a subset of papillary sinonasal carcinomas. The first identification of DEK-AFF2 fusion in squamous cell carcinoma occurred in tumors arising in the skull base and sinonasal region, where the tumors demonstrated unusual morphological features and, in one case, a remarkable response to immune checkpoint inhibitor therapy [24].

Histopathologically, tumors harboring the DEK-AFF2 fusion typically demonstrate basaloid to non-keratinizing epithelial cells arranged in papillary or inverted growth patterns. These tumors frequently display relatively uniform tumor cells with vesicular chromatin, increased mitotic activity, and focal areas of necrosis [25]. Additional architectural patterns such as inverted trabeculae, peripheral palisading, and complex papillary structures have also been described in several cases [26]. Some tumors demonstrate acantholytic changes that



create pseudopapillary or reticulum-like structures within tumor nests [27].

Despite their relatively bland cytological appearance, these tumors may exhibit aggressive biological behavior. Histological examination has revealed features including neutrophilic infiltrates, cellular whorls, squamoid morules, microcysts, and areas of clear cell change [28]. Such findings highlight the morphological diversity of DEK-AFF2 fusion-associated carcinomas and the potential for misinterpretation as benign lesions or papillomas during initial diagnosis.

The DEK gene is located on chromosome 6p22.3 and encodes a nuclear protein involved in chromatin organization and transcriptional regulation [29]. Overexpression of DEK has been implicated in several malignancies, including head and neck cancers, where it may contribute to cellular proliferation and oncogenic transformation [30]. The AFF2 gene, located on chromosome Xq28, encodes an RNA-binding protein that functions in transcriptional regulation and has previously been associated with fragile X-related disorders [31].

Formation of the DEK-AFF2 fusion gene is believed to result from chromosomal translocation events involving chromosomes 6 and X. The resulting chimeric protein contains functional domains derived from both genes and may retain the ability to interact with DNA and RNA molecules, potentially influencing transcriptional regulation and tumorigenesis [32]. Because breakpoints within the AFF2 gene differ from those observed in other DEK-related fusion events, commonly used sequencing panels designed for hematologic malignancies may fail to detect this fusion in squamous cell carcinomas [33].

From a diagnostic perspective, distinguishing DEK-AFF2 fusion-associated papillary carcinoma from sinonasal papilloma is critical. Sinonasal papillomas can demonstrate papillary and inverted growth patterns with inflammatory infiltrates, features that may resemble those observed in DEK-AFF2 tumors [34]. However, papillomas typically lack the complex labyrinth-like architecture and cytological uniformity seen in fusion-associated carcinomas. Furthermore, papilloma cells generally do not exhibit acantholytic changes or the degree of cellular monotony observed in DEK-AFF2 tumors [35].

Advances in next-generation sequencing technologies have enabled the identification of several molecularly defined tumor entities within the sinonasal tract. Among these, DEK-AFF2 fusion-associated carcinoma has recently been recognized as a distinct subtype of sinonasal squamous cell carcinoma [36]. Reported cases often demonstrate locally aggressive growth, frequent recurrence, and involvement of adjacent structures, including the skull base and paranasal sinuses [39].

Although histologically these tumors may appear deceptively low grade, clinical outcomes suggest that they should be considered malignant neoplasms requiring appropriate oncologic management. Some cases have demonstrated recurrence and high-grade transformation during the disease course, emphasizing the importance of accurate diagnosis and long-term clinical follow-up [52,53].

Human papillomavirus (HPV) is a well-established etiological factor in several head and neck cancers, particularly oropharyngeal squamous cell carcinoma [42]. However, the role of HPV in sinonasal squamous cell carcinoma remains less clearly defined. Epidemiological studies indicate that HPV may be present in approximately one-third of sinonasal squamous cell carcinomas, although the biological significance of this association remains uncertain [43].

Detection of HPV in tumor tissue can be achieved using several laboratory techniques, including nucleic acid hybridization assays, immunohistochemistry for p16 protein expression, polymerase chain reaction (PCR)-based amplification assays, and signal-amplification tests such as hybrid capture assays [44-47]. Detection of viral DNA alone does not necessarily indicate that HPV is responsible for tumorigenesis, and additional assays detecting transcriptionally active viral oncogenes such as E6 and E7 are often required to confirm causality [48,49]. Interestingly, many reported cases of DEK-AFF2 fusion-associated carcinomas have lacked molecular alterations typically seen in sinonasal papillomas, including EGFR and KRAS mutations, and have frequently tested negative for transcriptionally active HPV infection [41,50]. These findings suggest that this tumor entity may arise through molecular mechanisms distinct from both papilloma-associated carcinoma and HPV-driven squamous cell carcinoma.

Because only a limited number of cases have been reported, the natural history of DEK-AFF2 fusion-associated papillary carcinoma remains incompletely understood. Additional studies are required to determine whether these tumors represent a distinct biological entity or a variant within the spectrum of sinonasal squamous cell carcinoma [54].

Limitations of the evidence and review process

Several limitations should be considered when interpreting the findings of this systematic review. First, the number of available studies investigating DEK-AFF2 fusion-associated sinonasal carcinoma is small, reflecting the rarity of this tumor entity. Most published studies consist of case reports or small case series, which limits



the ability to draw definitive conclusions regarding prognosis and treatment outcomes.

Second, heterogeneity in diagnostic techniques, molecular testing methods, and clinical reporting across studies introduces variability that complicates direct comparison of findings. Some studies relied primarily on histopathological analysis, whereas others incorporated molecular sequencing techniques, potentially influencing reported results.

Third, limitations inherent to the review process should also be acknowledged. The literature search was restricted to studies published within a defined time period and available in selected electronic databases, which may have resulted in the exclusion of relevant studies indexed elsewhere. Additionally, because of the limited number of studies available, quantitative meta-analysis was not feasible, and the findings were synthesized qualitatively.

Implications for clinical practice and policy

Recognition of DEK-AFF2 fusion-associated papillary squamous cell carcinoma as a distinct molecular subtype of sinonasal carcinoma has important implications for diagnostic pathology and clinical management. Pathologists should consider molecular testing in cases of papillary sinonasal tumors with atypical morphology, particularly when conventional diagnostic features do not clearly distinguish between papilloma and carcinoma.

Identification of this fusion may also influence therapeutic decision-making. Early reports suggesting responsiveness to immune checkpoint inhibitors indicate that molecular characterization could guide personalized treatment strategies in selected patients.

From a broader clinical perspective, incorporation of molecular diagnostics into the routine evaluation of sinonasal tumors may improve diagnostic accuracy and facilitate identification of emerging tumor subtypes. Continued collaboration between pathologists, oncologists, and molecular researchers will be essential for establishing standardized diagnostic criteria and optimizing treatment strategies for these rare malignancies.

Future research should focus on multi-institutional studies with larger patient cohorts to clarify the biological mechanisms underlying DEK-AFF2 fusion-associated carcinogenesis, determine prognostic significance, and evaluate potential targeted therapies.

Conclusion

In conclusion, we present the first series of "DEK-AFF2-associated papillary squamous cell carcinoma (SCC) of the sinonasal tract." This series includes a subgroup of previously documented low-grade papillary squamous

cell carcinomas (LGPSCs) that surprisingly exhibit bland morphological characteristics. These tumors have a deceptively benign appearance and lack overt stromal invasion, which can lead to them being misidentified as sinonasal polyps (SPs) at their initial presentation, especially when compared to reported high-grade DEK-AFF2 fusion-positive carcinomas. The most significant diagnostic criteria identified for differentiation include the presence of strong neutrophilic infiltrates, focal acantholytic alterations, and broad papillary fronds. All cases tested were negative for recognized sinonasal polyp drivers, including both high- and low-risk HPV and EGFR/KRAS mutations, suggesting an entirely novel oncogenic driver mechanism. Typically, these tumors exhibit a protracted clinical course and advance locoregionally. They may also develop high-grade transformation or lymph node metastases, which indicate a need for more rigorous clinical treatment and classification as a carcinoma.

Registration and protocol

This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The review was not prospectively registered in an international systematic review registry such as PROSPERO, and a formal review protocol was not published before the initiation of the study.

Acknowledgement

The authors acknowledge the academic support provided by PSP Medical College Hospital and Research Institute, Tamil Nadu, India, which facilitated access to scientific databases and institutional resources used for the preparation of this systematic review.

List of abbreviations

SCC – Squamous Cell Carcinoma
OSCC – Oral Squamous Cell Carcinoma
PSCCA – Papillary Squamous Cell Carcinoma
SNSCC – Sinonasal Squamous Cell Carcinoma
HPV – Human Papillomavirus
DEK – DEK Proto-Oncogene
AFF2 – AF4/FMR2 Family Member 2
NGS – Next-Generation Sequencing
PCR – Polymerase Chain Reaction
IHC – Immunohistochemistry
CIS – Carcinoma in situ
CAF – Cancer-Associated Fibroblast
TGF- β – Transforming Growth Factor Beta
 α -SMA – Alpha Smooth Muscle Actin



PRISMA – Preferred Reporting Items for Systematic Reviews and Meta-Analyses

STROBE – Strengthening the Reporting of Observational Studies in Epidemiology

Support

No specific funding was received for this study. The review was conducted as part of the authors' academic and institutional research activities. The authors did not receive any financial or non-financial support from external funding bodies, and no sponsors were involved in the design, analysis, or preparation of the manuscript.

Competing interests

The authors declare that they have no competing interests related to this study.

Availability of data, code, and other materials

All data included in this systematic review were obtained from previously published studies available in the public domain. Extracted study data and summary tables used in the qualitative synthesis are available from the corresponding author upon reasonable request. No analytical code or specialized computational scripts were used in this review.

References

1. Nair S, Singh B, Pawar PV, Datta S, Nair D, Kane S, Chaturvedi P. Squamous cell carcinoma of tongue and buccal mucosa: clinico-pathologically different entities. *European Archives of Oto-Rhino-Laryngology*. 2016 Nov;273(11):3921-8. <https://doi.org/10.1007/s00405-016-4051-0> PMID:27098612
2. Warnakulasuriya S, Kujan O, Aguirre-Urizar JM, Bagan JV, González-Moles MÁ, Kerr AR, Lodi G, Mello FW, Monteiro L, Ogden GR, Sloan P. Oral potentially malignant disorders: A consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer. *Oral diseases*. 2021 Nov;27(8):1862-80. <https://doi.org/10.1111/odi.13704> PMID:33128420
3. Serra A, Caltabiano R, Scalia G, Palmucci S, Di Mauro P, Cocuzza S. Papillary squamous cell carcinoma of the palatine tonsil: a rare cancer of

the head and neck. *Acta Otorhinolaryngologica Italica*. 2017 Aug;37(4):341.

<https://doi.org/10.14639/0392-100X-1281>

PMid:28530265 PMCID:PMC5584108

4. Almangush A, Mäkitie AA, Triantafyllou A, de Bree R, Stojan P, Rinaldo A, Hernandez-Prera JC, Suárez C, Kowalski LP, Ferlito A, Leivo I. Staging and grading of oral squamous cell carcinoma: An update. *Oral oncology*. 2020 Aug 1;107:104799. <https://doi.org/10.1016/j.oraloncology.2020.104799> PMID:32446214
5. Sounni NE, Noel A. Targeting the tumor microenvironment for cancer therapy. *Clinical chemistry*. 2013 Jan 1;59(1):85-93. <https://doi.org/10.1373/clinchem.2012.185363> PMID:23193058
6. Xing F, Saidou J, Watabe K. Cancer-associated fibroblasts (CAFs) in tumor microenvironment. *Frontiers in bioscience: a journal and virtual library*. 2010 Jan 1;15:166. <https://doi.org/10.2741/3613> PMID:20036813 PMCID:PMC2905156
7. Kajdaniuk D, Marek B, Borgiel-Marek H, Kos-Kudła B. Transforming growth factor beta1 (TGFbeta1) in physiology and pathology. *Endokrynologia Polska*. 2013;64(5):384-96. <https://doi.org/10.5603/EP.2013.0022> PMID:24186596
8. Kadoya K, Togo S, Tulafu M, Namba Y, Iwai M, Watanabe J, Okabe T, Jin J, Kodama Y, Kitamura H, Ogura T. Specific features of fibrotic lung fibroblasts highly sensitive to fibrotic processes mediated via TGF- β -ERK5 interaction. *Cell Physiol Biochem*. 2019 Jan 1;52(4):822-37. <https://doi.org/10.33594/000000057> PMID:30946557
9. Shinde AV, Humeres C, Frangogiannis NG. The role of α -smooth muscle actin in fibroblast-mediated matrix contraction and remodeling. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease*. 2017 Jan 1;1863(1):298-309. <https://doi.org/10.1016/j.bbadis.2016.11.006> PMID:27825850 PMCID:PMC5163362
10. Thompson LD, Wenig BM, Heffner DK, Gnepp DR. Exophytic and papillary squamous cell carcinomas of the larynx: a clinicopathologic series of 104 cases. *Otolaryngology-Head and Neck Surgery*. 1999 May;120(5):718-24. <https://doi.org/10.1053/hn.1999.v120.a92773> PMID:10229599



11. Russell JO, Hoschar AP, Scharpf J. Papillary squamous cell carcinoma of the head and neck: a clinicopathologic series. *American journal of otolaryngology*. 2011 Nov 1;32(6):557-63. <https://doi.org/10.1016/j.amjoto.2010.09.010> PMID:21035908
12. Gnepp DR. *Diagnostic Surgical Pathology of the Head and Neck E-Book: Expert Consult-Online and Print*. Elsevier Health Sciences; 2009 May 31.
13. Cobo F, Talavera P, Concha Á. Relationship of human papillomavirus with papillary squamous cell carcinoma of the upper aerodigestive tract: a review. *International Journal of Surgical Pathology*. 2008 Apr;16(2):127-36. <https://doi.org/10.1177/1066896908314700> PMID:18387989
14. Suarez PA, Adler-Storthz K, Luna MA, El-Naggar AK, Abdul-Karim FW, Batsakis JG. Papillary squamous cell carcinomas of the upper aerodigestive tract: a clinicopathologic and molecular study. *Head & Neck: Journal for the Sciences and Specialties of the Head and Neck*. 2000 Jul;22(4):360-8. [https://doi.org/10.1002/1097-0347\(200007\)22:4<360::AID-HED8>3.0.CO;2-W](https://doi.org/10.1002/1097-0347(200007)22:4<360::AID-HED8>3.0.CO;2-W) PMID:10862019
15. Bao Z, Yang X, Shi L, Feng J, Liu W, Zhou Z. Clinicopathologic features of oral squamous papilloma and papillary squamous cell carcinoma: a study of 197 patients from eastern China. *Annals of Diagnostic Pathology*. 2012 Dec 1;16(6):454-8. <https://doi.org/10.1016/j.anndiagpath.2012.04.001> PMID:22627075
16. Ishiyama A, Ross DA, Raz Y, Kerner MM, Blackwell KE, Feneberg R, Bell TS, Calcaterra TC, Fu YS, Eversoles LR. Papillary squamous neoplasms of the head and neck. *The Laryngoscope*. 1994 Dec;104(12):1446-52. <https://doi.org/10.1288/00005537-199412000-00004> PMID:7990632
17. Takeda Y, Satoh M, Nakamura SI, Yamamoto H. Papillary squamous cell carcinoma of the oral mucosa: immunohistochemical comparison with other carcinomas of oral mucosal origin. *Journal of Oral Science*. 2001;43(3):165-9. <https://doi.org/10.2334/josnusd.43.165> PMID:11732736
18. Fitzpatrick SG, Neuman AN, Cohen DM, Bhattacharyya I. Papillary variant of squamous cell carcinoma arising on the gingiva: 61 cases reported from within a larger series of gingival squamous cell carcinoma. *Head and neck pathology*. 2013 Dec;7:320-6. <https://doi.org/10.1007/s12105-013-0444-1> PMID:23620148 PMID:PMC3824797
19. Vered M, Shnaiderman-Shapiro A, Zlotogorski-Hurvitz A, Salo T, Yahalom R. Cancer-associated fibroblasts in the tumor microenvironment of tongue carcinoma are a heterogeneous cell population. *Acta Histochemica*. 2019 Nov 1;121(8):151446. <https://doi.org/10.1016/j.acthis.2019.151446> PMID:31604589
20. Ding Y, Ma L, Shi L, Feng J, Liu W, Zhou Z. Papillary squamous cell carcinoma of the oral mucosa: a clinicopathologic and immunohistochemical study of 12 cases and literature review. *Annals of diagnostic pathology*. 2013 Feb 1;17(1):18-21. <https://doi.org/10.1016/j.anndiagpath.2012.04.005> PMID:22672806
21. Mukdad L, Heineman TE, Alonso J, Badran KW, Kuan EC, St. John MA. Oral tongue squamous cell carcinoma survival as stratified by age and sex: A Surveillance, Epidemiology, and results analysis. *The Laryngoscope*. 2019 Sep;129(9):2076-81. <https://doi.org/10.1002/lary.27720> PMID:30575045 PMID:PMC11484398
22. Jakobsson PÅ, Eneroth CM, Killander D, Moberger G, Mårtensson B. Histologic classification and grading of malignancy in carcinoma of the larynx. *Acta radiologica: therapy, physics, biology*. 1973 Jan 1;12(1):1-8. <https://doi.org/10.3109/02841867309131085> PMID:4725642
23. Mahmoud EA, Abdellatif MK, Mahmoud SA. Oral Papillary Squamous Cell Carcinoma and Oral Squamous Cell Carcinoma: A Histopathological and Immunohistochemical Comparative Study. *Head and Neck Pathology*. 2024 Jun 17;18(1):47. <https://doi.org/10.1007/s12105-024-01635-4> PMID:38884825 PMID:PMC11183025
24. Yang W, Lee KW, Srivastava RM, Kuo F, Krishna C, Chowell D, Makarov V, Hoen D, Dalin MG, Wexler L, Ghossein R. Immunogenic neoantigens derived from gene fusions stimulate T cell responses. *Nature medicine*. 2019 May;25(5):767-75. <https://doi.org/10.1038/s41591-019-0434-2> PMID:31011208 PMID:PMC6558662
25. Bishop JA, Gagan J, Paterson C, McLellan D, Sandison A. Nonkeratinizing squamous cell carcinoma of the sinonasal tract with DEK-AFF2: further solidifying an emerging entity.



- The American Journal of Surgical Pathology. 2021 May 1;45(5):718-20. <https://doi.org/10.1097/PAS.0000000000001596> PMID:33002918
26. Todorovic E, Truong T, Eskander A, Lin V, Swanson D, Dickson BC, Weinreb I. Middle ear and temporal bone nonkeratinizing squamous cell carcinomas with DEK-AFF2 fusion: an emerging entity. *The American journal of surgical pathology*. 2020 Sep 1;44(9):1244-50. <https://doi.org/10.1097/PAS.0000000000001498> PMID:32366754
27. Lewis Jr JS, Chernock RD, Haynes W, El-Mofty SK. Low-grade papillary schneiderian carcinoma, a unique and deceptively bland malignant neoplasm: report of a case. *The American Journal of Surgical Pathology*. 2015 May 1;39(5):714-21. <https://doi.org/10.1097/PAS.0000000000000390> PMID:25634744
28. Kuo YJ, Lewis Jr JS, Zhai C, Chen YA, Chernock RD, Hsieh MS, Lan MY, Lee CK, Weinreb I, Hang JF. DEK-AFF2 fusion-associated papillary squamous cell carcinoma of the sinonasal tract: clinicopathologic characterization of seven cases with deceptively bland morphology. *Modern Pathology*. 2021 Oct;34(10):1820-30. <https://doi.org/10.1038/s41379-021-00846-2> PMID:34108636
29. Von Lindern M, Fornerod M, Van Baal S, Jaegle M, De Wit T, Buijs A, Grosveld G. The translocation (6; 9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. *Molecular and cellular biology*. 1992 Apr 1;12(4):1687-97. <https://doi.org/10.1128/mcb.12.4.1687-1697.1992> PMID:1549122 PMCid:PMC369612
30. Bensaid M, Melko M, Bechara EG, Davidovic L, Berretta A, Catania MV, Gez J, Lalli E, Bardoni B. FRAXE-associated mental retardation protein (FMR2) is an RNA-binding protein with high affinity for G-quartet RNA-forming structure. *Nucleic acids research*. 2009 Mar 1;37(4):1269-79. <https://doi.org/10.1093/nar/gkn1058> PMCid:PMC2651778
31. Melko M, Douguet D, Bensaid M, Zongaro S, Verheggen C, Gez J, Bardoni B. Functional characterization of the AFF (AF4/FMR2) family of RNA-binding proteins: insights into the molecular pathology of FRAXE intellectual disability. *Human molecular genetics*. 2011 May 15;20(10):1873-85. <https://doi.org/10.1093/hmg/ddr069> PMID:21330300
32. Qin H, Malek S, Cowell JK, Ren M. Transformation of human CD34+ hematopoietic progenitor cells with DEK-NUP214 induces AML in an immunocompromised mouse model. *Oncogene*. 2016 Oct;35(43):5686-91. <https://doi.org/10.1038/onc.2016.118> PMID:27065320 PMCid:PMC5064821
33. Adams AK, Hallenbeck GE, Casper KA, Patil YJ, Wilson KM, Kimple RJ, Lambert PF, Witte DP, Xiao W, Gillison ML, Wikenheiser-Brokamp KA. DEK promotes HPV-positive and HPV-negative head and neck cancer cell proliferation. *Oncogene*. 2015 Feb;34(7):868-77. <https://doi.org/10.1038/onc.2014.15> PMID:24608431 PMCid:PMC4160430
34. Waldmann T, Scholten I, Kappes F, Hu HG, Knippers R. The DEK protein: an abundant and ubiquitous constituent of mammalian chromatin. *Gene*. 2004 Dec 8;343(1):1-9. <https://doi.org/10.1016/j.gene.2004.08.029> PMID:15563827
35. Wang H, Li H, Hu L, Zhou J, Zhai C, Wang D, Sun X. EGFR and KRAS mutations in Chinese patients with sinonasal inverted papilloma and oncocytic papilloma. *Histopathology*. 2019 Aug;75(2):274-81. <https://doi.org/10.1111/his.13868> PMID:30916792
36. Brown CS, Abi Hachem R, Pendse A, Madden JF, Francis HW. Low-grade papillary Schneiderian carcinoma of the sinonasal cavity and temporal bone. *Annals of Otolaryngology, Rhinology & Laryngology*. 2018 Dec;127(12):974-7. <https://doi.org/10.1177/0003489418803391> PMID:30269519
37. Jeong HJ, Roh J, Lee BJ, Cho KJ. Low-grade papillary Schneiderian carcinoma: a case report. *Head and Neck Pathology*. 2018 Mar;12:131-5. <https://doi.org/10.1007/s12105-017-0832-z> PMID:28639124 PMCid:PMC5873487
38. Carnevale S, Ferrario G, Sovardi F, Benazzo M, Morbini P. Low-grade papillary Schneiderian carcinoma: report of a case with molecular characterization. *Head and Neck Pathology*. 2020 Sep;14(3):799-802. <https://doi.org/10.1007/s12105-019-01067-5> sPMid:31473940 PMCid:PMC7413950
39. Williamson A, Sharma R, Cooper L, McGarry G. Low-grade papillary Schneiderian



- carcinoma; rare or under-recognised?. *Otolaryngology Case Reports*. 2019 Jun 1;11:100107.
<https://doi.org/10.1016/j.xocr.2019.02.001>
40. Zhai C, Wang H, Li S, Wang D. Clinicopathological analysis of low-grade papillary Schneiderian carcinoma: report of five new cases and review of the literature. *Histopathology*. 2021 Sep;79(3):370-80.
<https://doi.org/10.1111/his.14347>
PMid:33539575
41. Udager AM, McHugh JB, Goudsmit CM, Weigelin HC, Lim MS, Elenitoba-Johnson KS, Betz BL, Carey TE, Brown NA. Human papillomavirus (HPV) and somatic EGFR mutations are essential, mutually exclusive oncogenic mechanisms for inverted sinonasal papillomas and associated sinonasal squamous cell carcinomas. *Annals of Oncology*. 2018 Feb 1;29(2):466-71.
<https://doi.org/10.1093/annonc/mdx736>
PMid:29145573
42. Gelwan E, Malm IJ, Khararjian A, Fakhry C, Bishop JA, Westra WH. Nonuniform distribution of high-risk human papillomavirus in squamous cell carcinomas of the oropharynx: rethinking the anatomic boundaries of oral and oropharyngeal carcinoma from an oncologic HPV perspective. *The American Journal of Surgical Pathology*. 2017 Dec 1;41(12):1722-8.
<https://doi.org/10.1097/PAS.0000000000000929>
PMid:28877058
43. Bishop JA, Guo TW, Smith DF, Wang H, Ogawa T, Pai SI, Westra WH. Human papillomavirus-related carcinomas of the sinonasal tract. *The American journal of surgical pathology*. 2013 Feb 1;37(2):185-92.
<https://doi.org/10.1097/PAS.0b013e3182698673>
PMid:23095507 PMCID:PMC3545097
44. Smeets SJ, Hesselink AT, Speel EJ, Haesevoets A, Sniijders PJ, Pawlita M, Meijer CJ, Braakhuis BJ, Leemans CR, Brakenhoff RH. A novel algorithm for reliable detection of human papillomavirus in paraffin-embedded head and neck cancer specimens. *International journal of cancer*. 2007 Dec 1;121(11):2465-72.
<https://doi.org/10.1002/ijc.22980>
PMid:17680565
45. Westra WH. Detection of human papillomavirus in clinical samples. *Otolaryngologic Clinics of North America*. 2012 Aug 1;45(4):765-77.
<https://doi.org/10.1016/j.otc.2012.04.001>
PMid:22793851
46. Abreu AL, Souza RP, Gimenes F, Consolaro ME. A review of methods for detecting human Papillomavirus infection. *Virology journal*. 2012 Dec;9:1-9. <https://doi.org/10.1186/1743-422X-9-262>
PMid:23131123 PMCID:PMC3507852
47. Chowdhury N, Alvi S, Kimura K, Tawfik O, Manna P, Beahm D, Robinson A, Kerley S, Hoover L. Outcomes of HPV-related nasal squamous cell carcinoma. *The Laryngoscope*. 2017 Jul;127(7):1600-3.
<https://doi.org/10.1002/lary.26477>
PMid:28271500
48. Lewis Jr JS. Sinonasal squamous cell carcinoma: a review with emphasis on emerging histologic subtypes and the role of human papillomavirus. *Head and neck pathology*. 2016 Mar;10(1):60-7.
<https://doi.org/10.1007/s12105-016-0692-y>
PMid:26830402 PMCID:PMC4746138
49. Elgart K, Faden DL. Sinonasal squamous cell carcinoma: etiology, pathogenesis, and the role of human papillomavirus. *Current Otorhinolaryngology Reports*. 2020 Jun;8:111-9. <https://doi.org/10.1007/s40136-020-00279-6>
PMid:32582473 PMCID:PMC7314379
50. Udager AM, McHugh JB, Betz BL, Montone KT, Livolsi VA, Seethala RR, Yakirevich E, Iwenofu OH, Perez-Ordenez B, DuRoss KE, Weigelin HC. Activating KRAS mutations are characteristic of oncocytic sinonasal papilloma and associated sinonasal squamous cell carcinoma. *The Journal of Pathology*. 2016 Aug;239(4):394-8.
<https://doi.org/10.1002/path.4750>
PMid:27234382
51. Yamashita Y, Hasegawa M, Deng Z, Maeda H, Kondo S, Kyuna A, Matayoshi S, Agena S, Uehara T, Kouzaki H, Shimizu T. Human papillomavirus infection and immunohistochemical expression of cell cycle proteins pRb, p53, and p16 INK4a in sinonasal diseases. *Infectious agents and cancer*. 2015 Dec;10:1-8. <https://doi.org/10.1186/s13027-015-0019-8>
PMid:26244053 PMCID:PMC4524447
52. Ferrari M, Taboni S, Carobbio AL, Emanuelli E, Maroldi R, Bossi P, Nicolai P. Sinonasal squamous cell carcinoma, a narrative reappraisal of the current evidence. *Cancers*. 2021 Jun 7;13(11):2835.
<https://doi.org/10.3390/cancers13112835>
PMid:34200193 PMCID:PMC8201377



Student's Journal of Health Research Africa

e-ISSN: 2709-9997, p-ISSN: 3006-1059

Vol.7 No. 3 (2026): March 2026 Issue

<https://doi.org/10.51168/sjhrafrica.v7i3.2470>

Review Article

Page | 12

53. Saab-Chalhoub MW, Guo X, Shi Q, Chernock RD, Lewis Jr JS. Low-grade papillary sinonasal (Schneiderian) carcinoma: a series of five cases of a unique malignant neoplasm with comparison to inverted papilloma and conventional nonkeratinizing squamous cell carcinoma. *Head and Neck Pathology*. 2021 Dec;15(4):1221-34. <https://doi.org/10.1007/s12105-021-01335-3> PMID:34041710 PMCID:PMC8633211
54. Hang JF, Hsieh MS, Li WY, Chen JY, Lin SY, Liu SH, Pan CC, Kuo YJ. Human papillomavirus-related carcinoma with adenoid cystic-like features: a series of five cases expanding the pathological spectrum. *Histopathology*. 2017 Dec;71(6):887-96. <https://doi.org/10.1111/his.13301> PMID:28664668
55. Wartenberg M, Hool SL, Marrazzini A, Giger R, Rupp NJ. Differentiated papillary NUT carcinoma: an unexpected, deceptively bland presentation of a sinonasal carcinoma. *Head and neck pathology*. 2023 Sep;17(3):803-7. <https://doi.org/10.1007/s12105-023-01554-w> PMID:37118352 PMCID:PMC10513967

PUBLISHER DETAILS

Student's Journal of Health Research (SJHR)

(ISSN 2709-9997) Online

(ISSN 3006-1059) Print

Category: Non-Governmental & Non-profit Organization

Email: studentsjournal2020@gmail.com

WhatsApp: +256 775 434 261

**Location: Scholar's Summit Nakigalala, P. O. Box 701432,
Entebbe Uganda, East Africa**

